All News
ICYMI - The Pregnancy & Lactation Labeling Rule Explained
A recent article from Healio.com reviewed the FDA’s Pregnancy and Lactation Labeling Rule (PLLR) that became effective June 30th.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR 2020 Reproductive Guidelines - Medication Use with Pregnancy
The American College of Rheumatology (ACR) has published guidelines to manage reproductive health issues in rheumatic disease (RMD) patients before, during and after pregnancy.
Read Article
ICYMI - 11 Pearls for Pregnancy Management in Rheumatoid Arthritis
Rheumatoid arthritis affects women in their child-bearing years and many will face the issue of pregnancy and RA management at some point. Here are11 considerations for those managing RA patients who wish to become pregnant.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR 2020 Reproductive Guidelines - Contraception & Counseling
The American College of Rheumatology established a guidelines committee that consisted of both patients, rheumatologists and maternal-fetal health experts. After a a systematic review of the medical literature regarding contraception, assisted reproductive technology, fertility preservation, hormone replacement therapy pregnancy, lactation, and medication use in rheumatic disease patients, they published 12 good practice statements and 131 recommendations for reproductive health care in RMD patients.
Read Article
RheumNow Podcast – To Celiac Test or Not? (9.4.20)
Dr Jack Cush reviews the news, journal articles and takes a few Back Talk questions this week:
Read Article
Treatment Options for Extraintestinal IBD
Extraintestinal manifestations (EIMs) frequently accompany inflammatory bowel disease, often augmenting morbidity and mortality are associated with disease activity and may increase the need for surgery or treatment escalation. A recent review in GUT details the treatment options for patients with EIM.
Read Article
Early Cardiovascular Benefits to DMARD Treatment in Rheumatoid Arthritis
ARD has published a report showing that patients with early rheumatoid arthritis have cardiovascular disease that is modifiable with conventional and aggressive therapy and that it did not matter if first line DMARD therapy was with a tumour necrosis factor-inhibitor or methotrexate.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Rheum Lives Matter (8.28.20)
Dr. Jack Cush reviews the news and journal articles from the past week. Of mice and men in cartilage, the efficacy of JAK inhibitors in patients who are having skin problems, nrAxSpa has its own diagnostic code, metformin, talking about Back Talk, plus so much more.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatments Differ Across Centers in Systemic JIA
Significant variations were seen across hospitals in the treatment of children admitted with new-onset systemic juvenile idiopathic arthritis (JIA), despite increasing evidence of the efficacy of biologics and the hazards of extended glucocorticoid exposure, a retrospective cohort study found.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Update on Polymyalgia Rheumatica and Giant Cell Arteritis
JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has approved tocilizumab as a first-line glucocorticoid-sparing agent.
Read Article
Links:
Links:
Selective Biologic Responses in Seropositive RA
The Journal of Rheuatology reports a pooled analysis of patients from 16 observational RA registries that examined the association between seropositivity (RF or ACPA) with biologic DMARDs responses; they showed better clinical responses when seropositive RA patients receive abatacept (ABA) o
Read Article
RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.
Read Article